Previous investigations have shown that a high percentage of urine samples submitted to the laboratory contain antimicrobial substances.' 2 Two reports3 4 noted that the prevalence of antimicrobial substances in urine was 16-1 and 19-94%, respectively.
Millar and Langdale developed a procedure for identifying antimicrobial substances in urine, which may be used to investigate specimens demonstrating pyuria without bacterial growth. 4 There are several possible explanations as to why the remaining 31 (19-5%) were not detected. Additionally, 181 of 635 (28-5%) urine specimens without documented antibiotic use were positive. First, the documentation of antibiotics on the ordering requisition may have been incorrect-that is, instead of a patient being treated with antibiotics-the patient was not being treated or was going to be treated. This would mean that there were no antibiotics present at the time the specimen was collected. However, we believe the reported antibiotic information was accurate. Second, the concentration of antibiotic present may have been too low to be detected. Previously, Millar and Langdale4 found that antibiotic concentration in urine affected the pattern of inhibition zones for antibiotics used for treating urinary tract infections. Although their screening test was positive, the antibiotic concentration did affect this test. Third, the Urotest did not detect the presence of some antibiotics. This is the most unlikely reason as a comparison of the documented antibiotics in Urotest AB positive and negative urine specimens showed that similar types and frequency of the same antibiotics were used. Millar and Langdale4 reported that antimicrobial substances were found in 19-94% of 1514 urines tested. This is lower than the findings of this current study. The differences may be explained by the sensitivities of the two methods for detecting inhibitors. To our knowledge, such a comparison has not been carried out.
The value of a test that can detect inhibitors present in urine is considerable. It might explain why an individual with symptoms of urinary tract infection has negative urine cultures. From a different perspective, it may be of value in testing the success of a treatment and patient compliance. The ease of use and interpretation of the Urotest AB test would make this product easy to introduce into the clinical laboratory.
An important finding in this study is that the Urotest AB seems to detect inhibitors that were not accounted for by known antibiotics. The antibacterial activity of substances other than antibiotics has been reported. 56 We have no way of knowing if these inhibitors were, in fact, antimicrobial agents that were self administered or previously prescribed and not revealed during the current investigation. This information may help to explain treatment failure and the epidemiology of antimicrobial resistance.
